Moderate
Suspected
描述
Azithromycin inhibits CYP3A4-mediated aripiprazole metabolism, potentially increasing aripiprazole exposure; both drugs have modest QT-prolonging effects.
机制
Azithromycin is a mild-to-moderate CYP3A4 inhibitor; aripiprazole is metabolized by CYP3A4 and CYP2D6; increased plasma levels and additive QT effects may result.
临床意义
The QT prolongation risk is lower for aripiprazole than other antipsychotics, but the pharmacokinetic interaction can increase aripiprazole exposure meaningfully.
处理措施
Monitor for aripiprazole adverse effects (akathisia, sedation); an ECG is reasonable if prolonged co-administration is anticipated.